


JQKD82

Cat. No.:	HY-138691
CAS No.:	2410512-38-6
Molecular Formula:	C ₂₇ H ₄₀ N ₄ O ₅
Molecular Weight:	500.63
Target:	Histone Demethylase
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	JQKD82 (JADA82) is a cell-permeable and selective KDM5 inhibitor. JQKD82 increases H3K4me3 and can be used for the research of multiple myeloma ^[1] .								
IC₅₀ & Target	KDM5								
In Vitro	<p>JQKD82 (0.3 μM; 24 hours) causes an increase in the global H3K4me3 level of MM.1S cells^[1].</p> <p>JQKD82 (0.1-10 μM; day 1-day 5) inhibits the growth of MM.1S cells in a dose- and time-dependent manner. JQKD82 is potent at eliciting growth suppression in MM.1S cells (IC₅₀=0.42 μM)^[1].</p> <p>JQKD82 (1 μM; 24 hours) induces G1 cell-cycle arrest by 48 hours in MM.1S and MOLP-8 cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>JQKD82 (50-75 mg/kg; i.p.; twice a day for 3 weeks) has anti-multiple myeloma activity^[1].</p> <p>JQKD82 displays an increase in H3K4me3 levels and results in a dramatic reduction of MYC immuno-staining in vivo^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Six-week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (bearing MOLP-8 TurboGFP-Luc cells)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg, 75 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.; twice a day for 3 weeks</td> </tr> <tr> <td>Result:</td> <td>Significantly reduced tumor burden.</td> </tr> </table>	Animal Model:	Six-week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (bearing MOLP-8 TurboGFP-Luc cells) ^[1]	Dosage:	50 mg/kg, 75 mg/kg	Administration:	i.p.; twice a day for 3 weeks	Result:	Significantly reduced tumor burden.
Animal Model:	Six-week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (bearing MOLP-8 TurboGFP-Luc cells) ^[1]								
Dosage:	50 mg/kg, 75 mg/kg								
Administration:	i.p.; twice a day for 3 weeks								
Result:	Significantly reduced tumor burden.								

REFERENCES

[1]. Jun Qi, et al. Histone demethylase 5 inhibitors and uses thereof. WO2020033377A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA